STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Pharvaris N.V. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Pharvaris N.V. Schedule 13G/A discloses that a group of Venrock-related entities and two individuals beneficially own an aggregate of 2,047,620 ordinary shares of Pharvaris, representing 3.8% of the class as of June 30, 2025. The filing breaks this down as 380,109 shares held by Venrock Healthcare Capital Partners III, L.P., 38,028 by VHCP Co-Investment Holdings III, LLC, and 1,629,483 by Venrock Healthcare Capital Partners EG, L.P. The 3.8% percentage is calculated using 54,493,142 ordinary shares outstanding per the issuer's prospectus supplement dated July 22, 2025 (filed July 24, 2025). All entity filers are organized in Delaware; Nimish Shah and Bong Koh are U.S. citizens. The filing is signed on behalf of the reporting persons by Sherman G. Souther (authorized signatory) on August 14, 2025, and includes a certification that the securities were not acquired to influence control of the issuer.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Venrock group holds 2,047,620 shares (3.8%), a non-control passive stake reported for transparency.

The Schedule 13G/A shows an aggregate 3.8% beneficial ownership by Venrock-affiliated funds and named individuals as of June 30, 2025. The position is below the 5% threshold and the filing explicitly states the holdings were not acquired to influence control. The breakdown across funds identifies where economic exposure resides: VHCP EG holds the majority of the position. For investors, this is a disclosure of a modest institutional stake rather than a control or activist signal.

TL;DR: This is a routine joint 13G disclosure by a group asserting passive intent; governance impact appears limited.

The filing identifies a group of Venrock entities and two individuals filing jointly, with shared voting and dispositive power over 2,047,620 shares. The document includes standard powers of attorney and a joint filing agreement referenced by exhibits. Because the stake is under 5% and accompanied by a non-control certification, it signals disclosure compliance without immediate governance implications.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Venrock Healthcare Capital Partners III, L.P.
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date:08/14/2025
VHCP Co-Investment Holdings III, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
Date:08/14/2025
Venrock Healthcare Capital Partners EG, L.P.
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date:08/14/2025
VHCP Management III, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Authorized Signatory
Date:08/14/2025
VHCP Management EG, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Authorized Signatory
Date:08/14/2025
Nimish Shah
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Attorney-in-fact
Date:08/14/2025
Bong Y. Koh
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Attorney-in-fact
Date:08/14/2025
Exhibit Information

Exhibit 24.1 Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on November 30, 2023) Exhibit 24.2 Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on November 30, 2023) Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on November 30, 2023)

FAQ

How many Pharvaris (PHVS) shares does the Venrock group report owning?

The group reports beneficial ownership of 2,047,620 ordinary shares of Pharvaris.

What percentage of Pharvaris does the reported stake represent?

The reported stake represents 3.8% of Pharvaris ordinary shares, based on 54,493,142 shares outstanding.

Which Venrock entities hold the shares and what are the amounts?

Holdings are: 380,109 shares by VHCP III, 38,028 by VHCP Co-Investment III, and 1,629,483 by VHCP EG.

Does the filing indicate an intent to influence control of Pharvaris?

No. The certification states the securities were not acquired to influence control of the issuer.

Who signed the Schedule 13G/A on behalf of the reporting persons?

The filing was signed by Sherman G. Souther as authorized signatory on August 14, 2025.
Pharvaris N.V.

NASDAQ:PHVS

PHVS Rankings

PHVS Latest News

PHVS Latest SEC Filings

PHVS Stock Data

1.62B
40.34M
5.32%
76.36%
0.63%
Biotechnology
Healthcare
Link
Switzerland
Zug